The Rebif® (interferon beta-1a) Information Kit can help you and your healthcare provider decide if Rebif® is the right relapsing multiple sclerosis (RMS) treatment for you. This kit includes:
An overview of the safety profile and efficacy of Rebif®
†Attention Patients: Federal and state healthcare program beneficiaries are not eligible for the MS LifeLines® $0 co-pay program. If you participate in a federal or state healthcare program, including Medicare, Medicaid, TRICARE, the Department of Veterans Affairs, the Department of Defense, or any other similar federal or state healthcare program, including any state medical pharmaceutical assistance program, you are not eligible to utilize the MS LifeLines® $0 co-pay program.
IMPORTANT SAFETY INFORMATION AND INDICATION
Important Safety Information
Do not take Rebif if you are allergic to interferon beta, human albumin, or any of the ingredients in Rebif.
Rebif can cause serious side effects. Tell your healthcare provider right away if you have any of the symptoms listed below while taking Rebif.
Before you take Rebif, tell your healthcare provider if you have or have had any of the following conditions:
Tell your healthcare provider about all medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
The most common side effects of Rebif include:
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Rebif. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Rebif® (interferon beta-1a) is a prescription medicine used to treat relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is not known if Rebif is safe and effective in children.